PRN694 shows extended target residence time on ITK and RLK, enabling durable attenuation of effector cells in vitro and in vivo. PRN694 is an irreversible, highly selective, and effective covalent interleukin-2-inducible T-cell kinase (ITK) and resting ly
Diflomotecan (BN 80915) is a potent, orally active topoisomerase I inhibitor that displays enhanced plasma stability and superior preclinical anti-tumor activity relative to other established compounds.